Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Mindray Management Group Lowers Privatization Offer to $27 per ADS

publication date: Sep 10, 2015
Mindray Medical, the Shenzhen medical device company, reported a management-led group has lowered its offer to take the company private to $27 per ADS, a 10% drop from the $30 bid the group made in June. The revised offer values the company at $3.2 billion. The company's announcement did not give any reasons why the group lowered its offer. However, Mindray's growth rate has slowed to almost zero, and the outlook for China's economy has deteriorated, making the economic logic behind go-private transactions seem increasingly risky. More details....

Stock Symbol: (NYSE: MR)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital